– CANADA, Vancouver – Abattis Bioceuticals Corp. (CSE:ATT) (OTC:ATTBF) is pleased to announce the appointments of Kent McParland, Brazos Minshew, Shawn Balaghi and Jim Carter to the Company’s leadership team and Wolfgang Richter to its Board of Directors.
Chief Financial Officer & Chief Operating Officer
Kent McParland has been appointed as Chief Financial Officer and Chief Operating Officer, replacing David Whitney as Chief Financial Officer, and Rene David as Chief Operating Officer. Mr. McParland, a chartered professional accountant, joins Abattis following fifteen years in public practice with Grant Thornton, MNP and Deloitte. He has experience working in multiple industries and expertise in project management and change management.
Medical Advisory Committee & Corporate Advisory Board
Dr. Brazos Minshew has been appointed as Head of the Company’s Medical Advisory Board and as President of the Corporate Advisory Board of Vergence Naturals Ltd., a wholly-owned subsidiary of Abattis. In such roles, Mr. Minshew is expected to drive the sales and development of new formulations and to launch new brands and product offerings for the Company. Dr. Minshew is the author of four books with over one million copies sold, has more than 200 published articles, and is a proven researcher in the nutraceuticals space. Over the course of his career, the products he has developed have generated over US$4 billion in sales.
Mergers and Acquisitions Advisory
Jim Carter has been appointed as the Head of Mergers and Acquisitions Advisory and will drive the Company’s upcoming expansion activities and mergers and acquisitions strategy. Mr. Carter will also act as an advisor to the Board of Directors on financial matters. On the corporate side, Jim has deep experience with mergers and acquisitions, corporate and debt restructuring and risk management, having previously served as Vice President of an NYSE-listed merchant banking company for nearly twenty years.
Shawn Balaghi has been appointed as the Company’s Head of Corporate Development. Mr. Balaghi has over 20 years’ experience working with public markets and draws on a strong understanding of the cannabis space, having worked with numerous licensed producers under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Mr. Balaghi brings a wealth of experience and leadership to the corporate communications, capital markets and marketing teams.
“As we enter this next stage in our growth and development as a company, we are excited to be able to attract such talented and sought after individuals such as Kent, Brazos, Jim and Shawn,” stated Robert Abenante, President and CEO of Abattis. “The Company would also like to thank David Whitney and Rene David for their contributions as CFO and COO, respectively, and wish them the best in their future endeavors. Mr. David has served in several executive positions with Abattis and continues to serve on the Company’s Board of Directors,” added Mr. Abenante.
Board of Directors
Wolfgang Richter has been appointed as a director of the Company, bringing the number of directors of the Company to six. Mr. Richter draws on relevant experience with the cannabis industry, having previously served as a director of Northern Vine Canada Inc., a former subsidiary of the Company.
“The Company welcomes Mr. Richter to the Board of Directors,” commented Robert Abenante. “After serving with Wolfgang on the Board of Northern Vine, I am confident that his network and industry experience will add tremendous value to Abattis,” added Mr. Abenante.
About Abattis Bioceuticals Corp.
Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to the applicable laws of Canada and foreign jurisdictions.
For more information : http://www.abattis.com
- Disclaimer - News, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.
Comments are closed.